[4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid
C15H18IN3O4 — CID 134519421
Data last refreshed: (MolForge compound catalog, from PubChem)
About [4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid
[4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid (PubChem CID 134519421) has the molecular formula C15H18IN3O4 and a molecular weight of 431.23 g/mol. Its IUPAC name is [4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid.
Molecular Properties
| Compound Name | [4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid |
|---|---|
| PubChem CID | 134519421 |
| Molecular Formula | C15H18IN3O4 |
| Molecular Weight | 431.23 g/mol |
| Exact Mass | 431.03 |
| IUPAC Name | [4-(azetidin-1-yl)-4-oxobut-2-enyl]-[2-[(5-iodo-2-pyridinyl)oxy]ethyl]carbamic acid |
| SMILES | O=C(O)N(CC=CC(=O)N1CCC1)CCOc1ccc(I)cn1 |
| InChI | InChI=1S/C15H18IN3O4/c16-12-4-5-13(17-11-12)23-10-9-19(15(21)22)6-1-3-14(20)18-7-2-8-18/h1,3-5,11H,2,6-10H2,(H,21,22) |
| InChIKey | GXEWBAKAIKCPKP-UHFFFAOYSA-N |
| XLogP | 1.83 |
| TPSA | 82.97 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 431.23 |
| LogP ≤ 5 | 1.83 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'iodine', 'substructure': 'N/A'}, {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134519421 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.